A Phase 2 Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Conditions:   Previously Treated Metastatic Pancreatic Adenocarcinoma;   Pancreas Cancer Interventions:   Drug: Tadalafil;   Drug: Pembrolizumab;   Drug: Ipilimumab;   Drug: CRS-207 Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Lustgarten Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials